A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

NCT00910858 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

Interventions

DRUG: Lenalidomide
DRUG: Recombinant human erythropoietin

Sponsor

Celgene Corporation